BCLI Archives - Page 2 of 2 - Blue Horseshoe Stocks

Blue Horseshoe Stocks: BCLI Recap & More

BrainStorm Cell Therapeutics, Inc. BCLI

2015 is upon us and our first order of business is to address one of the stocks we tagged in Wednesday’s premarket report. BCLI had a strong session, as it pushed its way up from an early low of 4.02 to an aftyernoon high of 4.94; a solid +23% performance.

The strong session was apparently aided by the pre-emptive PR the company released which served as a reminder that results from Phase 2a trials of its ALS (Lou Gehrig’s Disease) treatment would be released on Monday. This morning the stock is gapping up wildly as anticipation grows, having already hit a premarket high of 7.28, which represents a total increase of 81% over the low we observed on New Year’s Eve.

Monday’s data release, which is expected to be positive, should most likely produce one of two effects. Either the results will beat expectations and facilitate another strong move, or they will fail to meet the mark and cause a pullback. In case of the latter, there may be rebound opportunities waiting just around the corner.

RedHill BioPharma Ltd. RDHL & NephroGenex, Inc. NRX

We also had this pair of standouts appear in Wednesday’s report, with each stock making a similar move. Both started the day with significant spikes in PPS, followed by a tapering off into the close.

RDHL made a sensational jump beginning almost immediately at the open running from 12.52 on up to 17.85 before its pullback, an intraday spike equaling 42.5%. Coincidentally, the stock ended the session having traded 42.5X its 3-month average volume.

NRX saw an initial low of 12.96, followed by a healthy 39% run to a high of 17.98. This play would offer one more opportunity in the form of an intraday swing as it came down and rebounded off of the 12.60-mark before returning to 15.15, an added 20% move, bringing the day’s cumulative total of possible gains to 59% .

Extended Watchlist:
CUR, ARWR, CLF, MSTX, RAD

Blue Horseshoe Stocks: Final Report of 2014

Good Morning Traders! Here it is- the final report of 2014! We had an amazing year, with huge gainers popping out of the woodwork left, right, and center! We want to take this opportunity to thank all of our readers for being a part of our community, wish you all a Happy New Year while reminding everyone that the best is yet to come… Each year our resolution remains the same: To make the upcoming year our best one ever! We’ve succeeded time and time again, and have no reason to believe that 2015 will be any different so be sure to stay with us! Cheers!

NeuroDerm Ltd. NDRM
NDRM exceeded all expectations yesterday after we caught it on an early morning news scan; it spent the entire day in full-on breakout mode setting records in both price and volume, trading almost 27X the norm over the six week period since the stock’s IPO.

Positive response to yesterday’s early morning press statement hurtled NDRM from an early low of 8.16 all the way up to 19.07 just prior to the close, making gains of up to 134% possible.

We’ll still be standing at the ready for an eventual course correction and chance for a dip-and-rip maneuver, but any way you slice it, NDRM is getting marked down as a huge winner. It’s a great way to close out what has, on the whole, been an absolutely stellar year.

NeuroDerm Announces Topline Results of Phase IIa Pharmacokinetic Study of ND0612H and ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson’s Disease (Tue 7:00AM EST)

Precious Metals on Watch: Gold, Silver

GDX and SLV have each been maintaining higher highs and higher lows since reaching a bottom in November. As we head into the New Year, we’re going to devote a good amount of focus to gold and silver, and tracking these indices and their options chains is going to be a good way to do that.

In particular, we’re going to be monitoring a few specific sets of contracts for each play:

SLV – March $15-15.50 Calls

GDX – March $17.50-$18 Calls

As you can see from the side-by-side chart we drew up below, GDX and SLV are looking similarly ripe. We’ve got SLV breaking the 50-Line on the RSI, and GDX following closely behind in that regard, we’re seeing testing of the 50DMA’s on both charts, and each of the MACD’s are giving the indication of bullish crosses.

Side Note:
We’re also going to radar HMCP, a sub-penny momentum play that has had an interesting past few sessions.

Extended Watchlist:
NRX, RDHL, MIG, CYTK, NEON, BCLI, CVEO

Blue Horseshoe Stocks: Options Review, MKHD Recap

Reviewing Friday’s Options Calls

First thing today, we’d like to rehash a portion of Friday’s report that we didn’t get a chance to discuss yesterday. Our regular followers will recall the added note we included regarding a few options trading ideas we were considering. As a result of favorable jobs numbers released that morning, we pointed out our interest in trading Calls in SPY, AA, ISRG, & GPRO.

Regardless of which selection one used to take advantage of the trend, it was met with potentially lucrative results. The dip-and-rip pattern we were on the lookout for showed itself across the board. For example, one of the biggest standouts out of the bunch were the SPY $195 weekly calls had traded as low as .52, and made it to roughly 2.00.

Moving forward, we’ve got another set of options to monitor. One of our favorite options trading cash-cows this year has been PBR, and yesterday the stock had a big bounce following last week’s selloff. As a result we’re going to radar November $16 Calls, and see if we can once again use PBR to our advantage as we have countless times already this year.

Mount Knowledge Holdings, Inc. MKHD

After a significant performance following our first mention of MKHD (Range: .042-.085 +102%) the stock has done a good job of maintaining higher levels of support, and we just wanted to re-state why we are so keen to follow this light volume trader.

The thing that mainly drew us to MKHD last week was the PR the company released regarding its acquisition of cyber-security firm Civergy, Inc; an outfit which generated revenues in excess of $35M last year. Further details of the deal were released in an 8-K on Wednesday, and we’re anxious to see what kind of lasting effect the merger will have on MKHD.

Extended Watchlist:
GTAT, GSAT, BCLI, ISR (Bottom Play)